These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7551920)

  • 21. Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.
    Vansteenkiste J; Vandebroek J; Mariën S; Roex L; Bertrand P; Bockaert J; De Beukelaar T; Deman R; De Muynck P; Ulrichts H
    Lung Cancer; 1995 Dec; 13(3):295-303. PubMed ID: 8719069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
    Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
    Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors.
    Kodani T; Ueoka H; Kiura K; Tabata M; Takigawa N; Segawa Y; Moritaka T; Hiraki S; Harada M; Tanimoto M
    Lung Cancer; 2002 Jun; 36(3):313-9. PubMed ID: 12009244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced non-small cell lung cancer chemotherapy: a randomized trial of two active regimens (MVP and PE).
    Ginopoulos P; Spyropoulos K; Kardamakis D; Dougenis D; Onyenadum A; Gogos CH; Solomou E; Chrysanthopoulos K
    Cancer Lett; 1997 Nov; 119(2):241-7. PubMed ID: 9570378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.
    Font A; Moyano AJ; Puerto JM; Tres A; Garcia-Giron C; Barneto I; Anton A; Sanchez JJ; Salvador A; Rosell R
    Cancer; 1999 Feb; 85(4):855-63. PubMed ID: 10091762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Partial substitution of cisplatin with carboplatin in combination with etoposide in advanced non-small cell lung cancer (NSCLC): a multicentric randomised phase II trial.
    Comella P; Frasci G; Panza N; De Cataldis G; Cioffi R; Curcio C; Nicolella D; Micillo E; Ianniello GP; Biondi E; Perchard J; Comella G
    Lung Cancer; 1996 Aug; 15(1):103-14. PubMed ID: 8865128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.
    Graziano SL; Valone FH; Herndon JE; Crawford J; Richards F; Rege VB; Clamon G; Green MR
    Lung Cancer; 1996 Jun; 14(2-3):315-29. PubMed ID: 8794413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
    Takada M; Fukuoka M; Ariyoshi Y; Furuse K; Niitani H; Ota K; Motomiya M; Hasegawa K; Tominaga K; Kuriyama T
    Cancer Chemother Pharmacol; 1992; 31(3):182-6. PubMed ID: 1281446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
    J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer.
    Ali MA; Kraut MJ; Valdivieso M; Wozniak AJ; Cummings G; Kalemkerian GP
    Cancer Invest; 2000; 18(1):1-5. PubMed ID: 10701360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
    Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
    Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
    Jelić S; Mitrović L; Radosavljević D; Elezar E; Babović N; Kovcin V; Tomasević Z; Kovacević S; Gavrilović D; Radulović S
    Lung Cancer; 2001 Oct; 34(1):1-13. PubMed ID: 11557107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
    Rosell R; Tonato M; Sandler A
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):27-34. PubMed ID: 9728582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
    Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
    J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
    Kosmidis P; Mylonakis N; Fountzilas G; Pavlidis N; Samantas E; Karabelis A; Kattis K; Skarlos D
    Ann Oncol; 1996 Jul; 7(5):517-20. PubMed ID: 8839908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
    Luedke DW; Einhorn L; Omura GA; Sarma PR; Bartolucci AA; Birch R; Greco FA
    J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
    Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
    Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.